neoag
Neoantigen × AI
Daily research signal
TOPICS / TUMOR TYPE

Melanoma

Melanoma — high mutational burden makes it the proving ground for personalized neoantigen vaccines, including the mRNA-4157 + pembrolizumab adjuvant program.

Topic58 items2026-07-11 – 2026-09-05
Tumor types
Melanoma58Glioblastoma9Liver cancer (HCC)6Lung cancer (NSCLC)6Head & neck cancer5Colorectal cancer5Pancreatic cancer5Breast cancer4Kidney cancer (RCC)2Ovarian cancer2Gastric cancer1Lynch syndrome1
01
Clinical

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation - finance.biggo.com

Moderna and Merck reported that their personalized mRNA cancer vaccine mRNA-4157 met its primary endpoint in the Phase 3 INTerpath-001 trial, which enrolled 1,137 high-risk melanoma patients after complete surgical resection. The vaccine combined with Keytruda produced statistically significant improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda monotherapy. The result added more than $50 billion in combined market value to the two companies, with Moderna’s stock rising 177% and adding about $44 billion, and is pushing oncology sequencing and diagnostics into the capital-markets spotlight. It also heightens speculation around Tempus AI’s Personalis bid and rivalry in the sequencing sector.

mRNA vaccinesModernaMerck
news · brief 2026-09-05 · published 2026-09-05
06
Clinical

A Neoantigen Vaccine for Melanoma? - NEJM Clinician

All rights reserved, including those for text and data mining, AI training, and similar technologies. The content of this site is intended for health care professionals. Harnessing the immune system through a vaccine to prevent recurrence of metastatic cancer has long been a tant…

news · brief 2026-09-02 · published 2025-12-15
12
Clinical

INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma - The ASCO Post

By The ASCO Post Staff Posted: 8/21/2026 10:29:00 AM Last Updated: 8/21/2026 9:47:23 AM Advertisement Merck and Moderna, Inc. have announced positive topline results from the phase III INTerpath-001 trial (ClinicalTrials.gov identifier NCT05933577) evaluating adjuvant treatment w…

mRNA vaccinesModernaMerck
news · brief 2026-08-28 · published 2026-08-21
14
Clinical

NTx Bio Powers Baylor College of Medicine's Manufacturing of a Personalized Cancer Vaccine in Diakonos Oncology's Phase 1 Refractory Melanoma Trial - BioSpace

NTxscribe CORE automates mRNA amplification of patient-derived tumor transcriptome, preserving full-length range of each patient’s tumor sequences in a personalized cancer vaccine workflow that is now dosing patients RIO RANCHO, N.M.--(BUSINESS WIRE)--NTx Bio, a leader in next-ge…

mRNA vaccines
news · brief 2026-08-28 · published 2026-08-19
21
Clinical

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too - Genetic Engineering and Biotechnology News

Intismeran autogene, an individualized neoantigen therapy, makes history on Wall Street as well as within the industry following its first positive Phase III data in a form of melanoma Investors of Merck & Co. (NYSE: MRK) and Moderna (Nasdaq: MRNA) were the most obvious—but not t…

mRNA vaccinesModernaMerck
news · brief 2026-08-27 · published 2026-08-23
24
Clinical

Personalized mRNA cancer vaccine shows promise in extending life span in melanoma trial - ABC11 News

Merck and Moderna announced that their personalized mRNA vaccine regimen successfully passed a large Phase 3 trial, reducing the risk of melanoma return or spread. While the FDA has not yet approved the treatment, the companies note it is the first combination regimen to demonstrate success in potentially extending lifespans for high-risk resected melanoma patients.

mRNA vaccinesModernaMerck
news · brief 2026-08-21 · published 2026-08-20
25
Clinical

Cancer vaccine prevents deadly melanoma from returning or spreading in landmark trial - Fox News

In the INTerpath-001 trial, 1,137 patients with resected stage IIB through IV melanoma were randomized to receive Keytruda plus the personalized vaccine or Keytruda plus placebo. The combination arm showed significantly better recurrence-free and distant metastasis-free survival, marking the first positive Phase 3 result for an mRNA-based personalized cancer therapy.

mRNA vaccines
news · brief 2026-08-21 · published 2026-08-20
26
Clinical

Moderna, Merck's Cancer Vaccine Breakthrough Raises Hope For New Wave Of Personalized Treatments - International Business Times

Moderna and Merck announced that intismeran autogene plus Keytruda met its primary endpoints of improving RFS and DMFS in a Phase 3 study of 1,137 high-risk melanoma patients. The personalized vaccine is designed to teach the immune system to target tumor-specific mutations, offering a mechanism distinct from chemotherapy or broad immunostimulation.

ModernaMerck
news · brief 2026-08-21 · published 2026-08-21
27
Clinical

Personalized cancer vaccine shows positive late-stage trial results - Scripps News

Moderna and Merck announced positive late-stage trial results for a personalized mRNA therapy combined with Keytruda in melanoma patients who had their cancer surgically removed. The companies plan to share full data at upcoming medical meetings, noting that the treatment aims to increase the possibility of cure by intervening early in the disease course.

mRNA vaccinesModernaMerck
news · brief 2026-08-21 · published 2026-08-19
28
Clinical

mRNA therapy found to prevent recurrence of melanoma - Lab + Life Scientist

The INTerpath-001 trial evaluated adjuvant intismeran autogene, an mRNA-based neoantigen therapy tailored to each patient's unique mutational signature, alongside pembrolizumab. Each dose contains synthetic mRNA coding for up to 34 neoantigens derived from the patient's tumor, aiming to activate a targeted anti-tumor immune response in patients with completely resected stage IIB–IV melanoma.

mRNA vaccines
news · brief 2026-08-21 · published 2026-08-21
29
Clinical

MSD-Moderna Phase III readout backs personalised mRNA neoantigen combination adjuvant therapy for melanoma - European Pharmaceutical Review

MSD and Moderna reported the first positive Phase III readout for an individualized neoantigen therapy (INT) combined with an mRNA-based cancer therapy. The data shows intismeran autogene plus pembrolizumab can facilitate longer cancer-free survival in completely resected stage IIB-IV melanoma compared to Keytruda alone.

mRNA vaccinesModerna
news · brief 2026-08-21 · published 2026-08-20
30
Clinical

Rob Davis: Individualized Neoantigen Therapy Transforms Adjuvant Melanoma Care - Oncodaily

Merck CEO Rob Davis highlighted the positive Phase 3 topline results for intismeran autogene plus Keytruda in the adjuvant setting for resected stage IIB-IV melanoma. He described the achievement as a defining moment for cancer research, validating the joint effort between Merck and Moderna scientists in developing this individualized neoantigen therapy.

ModernaMerck
news · brief 2026-08-21 · published 2026-08-21
31
Clinical

Moderna and Merck show personalized cancer vaccines can work. - Northeastern Global News

Moderna and Merck announced that their experimental personalized vaccine, combined with Keytruda, kept melanoma from spreading or returning longer than Keytruda alone in a trial of 1,137 patients. Experts describe the approach as highly promising for delaying recurrence and extending survival, with implications potentially reaching beyond melanoma to other cancer types.

ModernaMerck
news · brief 2026-08-21 · published 2026-08-20
54
AI / Methods

Engineering editopes through programmable RNA editing toward tumor neoantigen generation.

Researchers developed SPEAR gRNAs to harness endogenous ADAR1 for precise A-to-I RNA editing, creating immunogenic neoepitopes termed 'editopes.' In a melanoma model using the MART-1 antigen, this approach restored T-cell recognition and enabled tumor control in vivo. The team also established a computational pipeline to identify candidate tumor-selective neoepitopes across multiple cancer types.

europepmc · brief 2026-08-16 · published 2026-08-14
55
Clinical

Individualized Neoantigen Therapy/Pembrolizumab Improves RFS in Melanoma - CancerNetwork

Follow-up data from the phase 2b KEYNOTE-942 trial shows that BioNTech’s mRNA-4157 combined with pembrolizumab reduced the risk of recurrence or death by 49% in high-risk stage III/IV melanoma patients compared to pembrolizumab alone. The combination also cut the risk of distant metastases or death by 62% at a median follow-up of three years. These results support the clinical benefit of personalized neoantigen mRNA vaccines in adjuvant settings.

mRNA vaccinesModernaBioNTech
news · brief 2026-08-07 · published 2023-12-18
58
AI / Methods

Spatial Compartmentalization of TCR Repertoires Between Primary Melanomas and Sentinel Lymph Nodes Reveals Distinct Clonal Architectures and Shared Antigen Recognition

Primary tumors and their sentinel lymph nodes are functionally linked sites of anti-tumor immunity, yet how T cell receptor (TCR) repertoires are organized across these compartments remains incompletely understood. We thus performed TCR{beta} sequencing on paired primary melanoma…

TCR & T-cell receptorShared & off-the-shelf
biorxiv · brief 2026-07-11 · published 2026-07-08
Where nextAll topicsToday’s briefTrials tracker